Live Breaking News & Updates on Savara pharmaceuticals

Stay informed with the latest breaking news from Savara pharmaceuticals on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Savara pharmaceuticals and stay connected to the pulse of your community

LaVoieHealthScience | O'Dwyer's PR Firms Directory

Premier database and directory of PR firms & public relations agencies. Find the firm that best suits your needs.

Miami , Florida , United-states , Toronto , Ontario , Canada , New-york , Cambridge , Cambridgeshire , United-kingdom , Park-plaza , Massachusetts

Inhaled Antibiotics Market to Surpass US$ 2,213.2 Million by 2030, Says Coherent Market Insights

Inhaled Antibiotics Market to Surpass US$ 2,213.2 Million by 2030, Says Coherent Market Insights
einnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from einnews.com Daily Mail and Mail on Sunday newspapers.

India , Mumbai , Maharashtra , Russia , Italy , South-africa , United-states , United-kingdom , Mexico , China , Israel , Germany

Global Peptide Antibiotics Market Report 2022: Sector to Reach $5.74 Billion in 2026 at a CAGR of 8%

/PRNewswire/ -- The "Peptide Antibiotics Global Market Report 2022: Ukraine-Russia War Impact" report has been added to ResearchAndMarkets.com's offering. This...

France , South-korea , Indonesia , Brazil , United-states , United-kingdom , Australia , Dublin , Ireland , Japan , Berkeley , California

Peptide Antibiotics Market – Major Revenue Gains are Expected by 2029

Impact of COVID-19 on the Healthcare IndustryThe COVID-19 pandemic has caused severe impacts on the global economy at various levels and which can be seen on the Healthcare industry as well. The thriving market of health care research and development is expected to exhibit a steep decline in the sales during the loc...

New-york , United-states , Delaware , America , Theravance-biopharma , Eli-lilly , Vicuron-pharmaceuticals , Glaxosmithkline-plc , Drug-stores , Savara-pharmaceuticals , Novartis , Market-insights-inc

Acute Respiratory Distress Syndrome (ARDS) - Market Outlook, Epidemiology, Competitive Landscape and Market Forecast Report 2020 to 2030

Acute Respiratory Distress Syndrome (ARDS) – Market Outlook, Epidemiology, Competitive Landscape and Market Forecast Report 2020 to 2030

Germany , Japan , United-states , India , United-kingdom , China , Italy , France , Spain , Chiesi-farmacetuci , Entwicklung-gmb , Techpool-bio-pharma

Acute Respiratory Distress Syndrome (ARDS) - Market Outlook, Epidemiology, Competitive Landscape and Market Forecast Report 2020 to 2030

Acute Respiratory Distress Syndrome (ARDS) – Market Outlook, Epidemiology, Competitive Landscape and Market Forecast Report 2020 to 2030

Germany , Japan , United-states , India , United-kingdom , China , Italy , France , Spain , Chiesi-farmacetuci , Entwicklung-gmb , Techpool-bio-pharma

Form DEF 14A Savara Inc For: Jun 10

Form DEF 14A Savara Inc For: Jun 10
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

New-jersey , United-states , Wayne-state-university-school-of-medicine , Michigan , Delaware , California , Edgewood , Texas , San-francisco , Berkeley , National-institutes-of-health , Maryland

Lumos Pharma Announces Changes to its Board of Directors


Share:
AUSTIN, Texas, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced the appointment of An van Es-Johansson, M.D., to its Board of Directors, effective immediately, where she will serve as a member of the Nominating and Governance Committee. Dr. van Es-Johansson brings over 30 years of experience in executive and clinical development roles in the pharmaceutical industry. Dr. van Es-Johansson will succeed Emmett Cunningham who is resigning his Board position to focus on other professional obligations in his managerial role at Blackstone Life Sciences.
"We are excited to welcome Dr. An van Es-Johansson to our Board," said Rick Hawkins, CEO, President and Chairman. "Dr. van Es-Johansson's clinical and corporate experience focused on growth hormone disorders and other rare diseases will be of immense value to Lumos Pharma as we pursue our clinical and business development programs targeting this same area. We also greatly appreciate Emmett Cunningham's tenure as a Lumos Pharma Board member. His guidance served Lumos Pharma well, particularly through our transition last year to a publicly listed company, and we wish Emmett the very best in his ventures hereafter."

Sweden , Netherlands , Stockholm , Texas , United-states , Swedish , Rick-hawkins , Uppsala-bio , Eli-lily , Alzecure-pharma , Lisa-miller , Emmett-cunningham